All In Biotech

Drug Trial Radar · NCT06180889

Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty

An Open, Randomized, Active-comparator-controlled, Multicenter Study to Assess the Efficacy and Safety of Different Doses of KN060 for the Prevention of Venous Thromboembolism in Patients Undergoing Unilateral Total Knee Arthroplasty.

Last checked: Nov 19, 2026Latest source record: Sep 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 241 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

241

Actual

Start

Dec 20, 2023

Primary completion

Dec 15, 2025

Study completion Apr 15, 2026

Sponsor

Lead sponsor
Suzhou Alphamab Co., Ltd.Industry
Sponsor type
Industry
First posted
Dec 26, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was to compare the study drug KN060 to enoxaparin, for the prevention of blood clotting and safety in patients undergoing total knee arthroplasty (TKA).

Conditions

  • Knee Arthroplasty, Total

Interventions

  • EnoxaparinDrug

    40 mg enoxaparin administered as subcutaneous injection once daily

  • KN060 LowDrug

    Single dose of KN060 administered as intravenous infusion

  • KN060 MiddleDrug

    Single dose of KN060 administered as intravenous infusion

  • KN060 HightDrug

    Single dose of KN060 administered as intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of composite endpoint consisting of asymptomatic DVT as detected by mandatory bilateral venography, objectively confirmed symptomatic DVT, non-fatal PE, fatal PE, unexplained death for which PE cannot be excludedTime frame: Up to 14 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Sixth People's Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.